Progress in Neuro-Psychopharmacology and Biological Psychiatry
January 15, 2011
Jaime E. C. Hallak, Serdar Dursun, Daniel C Bosi et al.
Interactions between glutamatergic and endocannabinoid systems may contribute to schizophrenia, dissociative states, and other psychiatric conditions. Cannabidiol (CBD), a cannabinoid-1/2 (CB1/2) receptor weak partial agonist or antagonist, may play a role in the treatment of schizophrenia. This study tested the hypothesis that CBD would attenuate the behavioral effects of the NMDA receptor...
The British Journal of Psychiatry
October 2010
Celia J. A. Morgan, Gráinne Schäfer, Tom P. Freeman et al.
The two main constituents of cannabis, cannabidiol and Δ(9)-tetrahydrocannabinol (THC), have opposing effects both pharmacologically and behaviourally when administered in the laboratory. Street cannabis is known to contain varying levels of each cannabinoid. To study how the varying levels of cannabidiol and THC have an impact on the acute effects of the drug in naturalistic settings. Cannabis...
The British Journal of Psychiatry
September 30, 2010
Cécile Henquet, Rebecca Kuepper
16 citations
A recent study by Morgan and colleagues found that cannabidiol attenuates the acute cognitive effects of delta-9-tetrahydrocannabinol (THC). This is of interest as THC has been associated with the detrimental effects of cannabis on mental health in at-risk users, and the potency of cannabis is increasing across Europe.
Neuropsychopharmacology
August 2010
Celia J A Morgan, Tom P. Freeman, Gráinne Schäfer et al.
Worldwide cannabis dependence is increasing, as is the concentration of Delta(9)-tetrahydrocannabinol (THC) in street cannabis. At the same time, the concentration of the second most abundant cannabinoid in street cannabis, cannabidiol (CBD), is decreasing. These two cannabinoids have opposing effects both pharmacologically and behaviorally when administered in the laboratory. No research has...
The International Journal of Neuropsychopharmacology
August 2010
Leonora E Long, Rose Chesworth, Xu-Feng Huang et al.
Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing schizophrenia. The behavioural profiles of the psychotropic cannabis constituent Delta9-tetrahydrocannabinol (Delta9-THC) and the non-psychotomimetic constituent cannabidiol (CBD) were investigated with a battery of behavioural tests relevant to anxiety and positive, negative and cognitive...
Brazilian Journal of Psychiatry
March 1, 2010
Jaime E. C. Hallak, João Paulo Machado‐de‐Sousa, José Alexandre S. Crippa et al.
122 citations
OBJECTIVE: The last decade has seen increasing evidence of dysfunctions in the endogenous cannabinoid system in schizophrenia and of its relationship with the typical cognitive impairment of the disorder. Studies in animal models, healthy volunteers, and psychotic patients clearly suggest an antipsychotic-like effect of cannabidiol. This study investigated the effects of cannabidiol on...
Neuropsychopharmacology
November 18, 2009
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.
The International Journal of Neuropsychopharmacology
September 24, 2009
Paolo Fusar‐poli, Paul Allen, Sagnik Bhattacharyya et al.
165 citations
Cannabis sativa, the most widely used illicit drug, has profound effects on levels of anxiety in animals and humans. Although recent studies have helped provide a better understanding of the neurofunctional correlates of these effects, indicating the involvement of the amygdala and cingulate cortex, their reciprocal influence is still mostly unknown. In this study dynamic causal modelling (DCM)...
Pharmacology, Biochemistry, and Behavior
August 2009
Daniel Thomas Malone, Dennis Jongejan, David Alan Taylor
While Delta(9)-tetrahydrocannabinol (THC) is the main psychoactive constituent of the cannabis plant, a non-psychoactive constituent is cannabidiol (CBD). CBD has been implicated as a potential treatment of a number of disorders including schizophrenia and epilepsy and has been included with THC in a 1:1 combination for the treatment of conditions such as neuropathic pain. This study...
European Psychiatry
2009
C. Morgan
Cannabis contains a myriad of different chemicals, more than 60 of which are unique to the plant and called cannabinoids. The main psychoactive ingredient is delta9-tetrahydrocannabinol (THC) and this produces the effects that users seek (Curran et al., 2002 Psychopharmacology 164: 61-70). When given intravenously to healthy humans, THC produces psychotic-like and anxiogenic effects (D’Souza et...